Search Results - "Mitsiades, Constantine. S"

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc by Delmore, Jake E., Issa, Ghayas C., Lemieux, Madeleine E., Rahl, Peter B., Shi, Junwei, Jacobs, Hannah M., Kastritis, Efstathios, Gilpatrick, Timothy, Paranal, Ronald M., Qi, Jun, Chesi, Marta, Schinzel, Anna C., McKeown, Michael R., Heffernan, Timothy P., Vakoc, Christopher R., Bergsagel, P. Leif, Ghobrial, Irene M., Richardson, Paul G., Young, Richard A., Hahn, William C., Anderson, Kenneth C., Kung, Andrew L., Bradner, James E., Mitsiades, Constantine S.

“…MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist. Toward this…”
Get full text

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins by Lu, Gang, Middleton, Richard E., Sun, Huahang, Naniong, MarkVic, Ott, Christopher J., Mitsiades, Constantine S., Wong, Kwok-Kin, Bradner, James E., Kaelin, William G.

“…Thalidomide-like drugs such as lenalidomide are clinically important treatments for multiple myeloma and show promise for other B cell malignancies. The…”
Get full text

An epigenomic approach to therapy for tamoxifen-resistant breast cancer by Feng, Qin, Zhang, Zheng, Shea, Martin J, Creighton, Chad J, Coarfa, Cristian, Hilsenbeck, Susan G, Lanz, Rainer, He, Bin, Wang, Lei, Fu, Xiaoyong, Nardone, Agostina, Song, Yongcheng, Bradner, James, Mitsiades, Nicholas, Mitsiades, Constantine S, Osborne, C Kent, Schiff, Rachel, O'Malley, Bert W

“…Tamoxifen has been a frontline treatment for estrogen receptor alpha （ERα）-positive breast tumors in premenopausal women. However, resistance to tamoxifen…”
Get full text

Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology by Mitsiades, Constantine S.

“…In this issue of Cancer Cell, Zhang et al. report that TJP1 suppresses EGFR/JAK1/STAT3-mediated signaling and increases the proteasome inhibitor sensitivity of…”
Get full text

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation by Roth, Michael, Will, Britta, Simkin, Guillermo, Narayanagari, Swathi, Barreyro, Laura, Bartholdy, Boris, Tamari, Roni, Mitsiades, Constantine S., Verma, Amit, Steidl, Ulrich

“…Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia…”
Get full text

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma by Le Moigne, Ronan, Aftab, Blake T, Djakovic, Stevan, Dhimolea, Eugen, Valle, Eduardo, Murnane, Megan, King, Emily M, Soriano, Ferdie, Menon, Mary-Kamala, Wu, Zhi Yong, Wong, Stephen T, Lee, Grace J, Yao, Bing, Wiita, Arun P, Lam, Christine, Rice, Julie, Wang, Jinhai, Chesi, Marta, Bergsagel, P Leif, Kraus, Marianne, Driessen, Christoph, Kiss von Soly, Szerenke, Yakes, F Michael, Wustrow, David, Shawver, Laura, Zhou, Han-Jie, Martin, 3rd, Thomas G, Wolf, Jeffrey L, Mitsiades, Constantine S, Anderson, Daniel J, Rolfe, Mark

“…Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system, and CB-5083, a first-in-class…”
Get full text

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS by Barreyro, Laura, Will, Britta, Bartholdy, Boris, Zhou, Li, Todorova, Tihomira I., Stanley, Robert F., Ben-Neriah, Susana, Montagna, Cristina, Parekh, Samir, Pellagatti, Andrea, Boultwood, Jacqueline, Paietta, Elisabeth, Ketterling, Rhett P., Cripe, Larry, Fernandez, Hugo F., Greenberg, Peter L., Tallman, Martin S., Steidl, Christian, Mitsiades, Constantine S., Verma, Amit, Steidl, Ulrich

“…Cellular and interpatient heterogeneity and the involvement of different stem and progenitor compartments in leukemogenesis are challenges for the…”
Get full text

NF-κB dysregulation in multiple myeloma by Matthews, Geoffrey M., Ph.D, de Matos Simoes, Ricardo, Ph.D, Dhimolea, Eugen, Ph.D, Sheffer, Michal, Ph.D, Gandolfi, Sara, M.D, Dashevsky, Olga, Ph.D, Sorrell, Jeffrey D., B.A, Mitsiades, Constantine S., M.D., Ph.D

“…Abstract The nuclear factor-κB (NF-κB) transcription factor family plays critical roles in the pathophysiology of hematologic neoplasias, including multiple…”
Get full text

The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells by Zhu, Di, Wang, Zhongqiu, Zhao, Jian-Jun, Calimeri, Teresa, Meng, Jiang, Hideshima, Teru, Fulciniti, Mariateresa, Kang, Yue, Ficarro, Scott B, Tai, Yu-Tzu, Hunter, Zachary, McMilin, Douglas, Tong, Haoxuan, Mitsiades, Constantine S, Wu, Catherine J, Treon, Steven P, Dorfman, David M, Pinkus, Geraldine, Munshi, Nikhil C, Tassone, Pierfrancesco, Marto, Jarrod A, Anderson, Kenneth C, Carrasco, Ruben D

“…Cyclophilin A, secreted by bone marrow endothelial cells, acts as a chemotactic factor for myeloma cells, which helps explain their homing to the bone marrow…”
Get full text

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma by Blotta, Simona, Jakubikova, Jana, Calimeri, Teresa, Roccaro, Aldo M., Amodio, Nicola, Azab, Abdel Kareem, Foresta, Umberto, Mitsiades, Constantine S., Rossi, Marco, Todoerti, Katia, Molica, Stefano, Morabito, Fortunato, Neri, Antonino, Tagliaferri, Piersandro, Tassone, Pierfrancesco, Anderson, Kenneth C., Munshi, Nikhil C.

“…The Hedgehog (Hh) pathway is required for cell-fate determination during the embryonic life, as well as cell growth and differentiation in the adult organism,…”
Get full text

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers by Richardson, Paul G., Mitsiades, Constantine S., Laubach, Jacob P., Lonial, Sagar, Chanan‐Khan, Asher A., Anderson, Kenneth C.

“…Summary Heat shock protein 90 (HSP90) is a molecular chaperone that is induced in response to cellular stress and stabilizes client proteins involved in cell…”
Get full text

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex by He, Bin, Lanz, Rainer B., Fiskus, Warren, Geng, Chuandong, Yi, Ping, Hartig, Sean M., Rajapakshe, Kimal, Shou, John, Wei, Liping, Shah, Shrijal S., Foley, Christopher, Chew, Sue Anne, Eedunuri, Vijay K., Bedoya, Diego J., Feng, Qin, Minami, Takashi, Mitsiades, Constantine S., Frolov, Anna, Weigel, Nancy L., Hilsenbeck, Susan G., Rosen, Daniel G., Palzkill, Timothy, Ittmann, Michael M., Song, Yongcheng, Coarfa, Cristian, O'Malley, Bert W., Mitsiades, Nicholas

“…The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC) and frequently even after treatment…”
Get full text

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications by Jakubikova, Jana, Adamia, Sophia, Kost-Alimova, Maria, Klippel, Steffen, Cervi, David, Daley, John F., Cholujova, Dana, Kong, Sun-Young, Leiba, Merav, Blotta, Simona, Ooi, Melissa, Delmore, Jake, Laubach, Jacob, Richardson, Paul G., Sedlak, Jan, Anderson, Kenneth C., Mitsiades, Constantine S.

“…Recurrence of multiple myeloma (MM) after therapy suggests the presence of tumor-initiating subpopulations. In our study, we performed flow cytometry–based…”
Get full text

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation by Weinstock, Mathew, Aljawai, Yosra, Morgan, Elizabeth A., Laubach, Jacob, Gannon, Muriel, Roccaro, Aldo M., Varga, Cindy, Mitsiades, Constantine S., Paba‐Prada, Claudia, Schlossman, Robert, Munshi, Nikhil, Anderson, Kenneth C., Richardson, Paul P., Weller, Edie, Ghobrial, Irene M.

“…Summary Extramedullary disease (EMD), defined as an infiltrate of clonal plasma cells at an anatomic site distant from the bone marrow, is an uncommon…”
Get full text

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment by Lam, Christine, Ferguson, Ian D, Mariano, Margarette C, Lin, Yu-Hsiu T, Murnane, Megan, Liu, Hui, Smith, Geoffrey A, Wong, Sandy W, Taunton, Jack, Liu, Jun O, Mitsiades, Constantine S, Hann, Byron C, Aftab, Blake T, Wiita, Arun P

“…The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is…”
Get full text

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma by RICHARDSON, Paul G, WELLER, Edie, WARREN, Diane L, LUNDE, Laura E, MCKENNEY, Mary, DELANEY, Carol, MITSIADES, Constantine S, HIDESHIMA, Teru, DALTON, William, KNIGHT, Robert, ESSELTINE, Dixie-Lee, ANDERSON, Kenneth C, JAGANNATH, Sundar, AVIGAN, David E, ALSINA, Melissa, SCHLOSSMAN, Robert L, MAZUMDER, Amitabha, MUNSHI, Nikhil C, GHOBRIAL, Irene M, DOSS, Deborah

“…Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to…”
Get full text

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma by Mitsiades, Constantine S, Davies, Faith E, Laubach, Jacob P, Joshua, Douglas, San Miguel, Jesus, Anderson, Kenneth C, Richardson, Paul G

“…Despite tangible progress in recent years, substantial therapeutic challenges remain in multiple myeloma (MM), particularly for patients at high risk for early…”
Get full text

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors by Mitsiades, Constantine S, Mitsiades, Nicholas S, McMullan, Ciaran J, Poulaki, Vassiliki, Shringarpure, Reshma, Akiyama, Masaharu, Hideshima, Teru, Chauhan, Dharminder, Joseph, Marie, Libermann, Towia A, Garcı́a-Echeverrı́a, Carlos, Pearson, Mark A, Hofmann, Francesco, Anderson, Kenneth C, Kung, Andrew L

“…Insulin-like growth factors and their receptor (IGF-1R) have been implicated in cancer pathophysiology. We demonstrate that IGF-1R is universally expressed in…”
Get full text

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 by MCMILLIN, Douglas W, OOI, Melissa, MUNSHI, Nikhil C, RICHARDSON, Paul G, ANDERSON, Kenneth C, MITSIADES, Constantine S, DELMORE, Jake, NEGRI, Joseph, HAYDEN, Patrick, MITSIADES, Nicolas, JAKUBIKOVA, Jana, MAIRA, Sauveur-Michel, GARCIA-ECHEVERRIA, Carlos, SCHLOSSMAN, Robert

“…The phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway mediates proliferation, survival, and drug resistance in multiple…”
Get full text

H2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia by Kawahara, Masahiro, Pandolfi, Ashley, Bartholdy, Boris, Barreyro, Laura, Will, Britta, Roth, Michael, Okoye-Okafor, Ujunwa C., Todorova, Tihomira I., Figueroa, Maria E., Melnick, Ari, Mitsiades, Constantine S., Steidl, Ulrich

“…Homeobox domain-containing transcription factors are important regulators of hematopoiesis. Here, we report that increased levels of nonclustered H2.0-like…”
Get full text